Abstract:
본 발명은 김치에서 분리된 신규 락토바실러스속 균주를 제공한다. 본 발명에 따른 특정 바실러스속 균주는 김치에서 분리되어 안전성이 높고, 우수한 항비만 활성, 혈중 콜레스테롤 저하 활성, 혈중 중성지질 저하 활성 또는 항산화 활성 등과 같은 다양한 기능성을 갖는다. 따라서, 본 발명에 따른 특정 바실러스속 균주는 비만, 지방간, 제2형 당뇨, 고지혈증, 심혈관 질환, 동맥경화증 및 지질 관련 대사증후군과 같은 질환을 예방, 개선 또는 치료하는데에 유용한 식의약 소재로 사용될 수 있다. 나아가, 본 발명에 따른 특정 바실러스속 균주로 대두, 더덕, 인삼 및 산수유씨를 발효시킨 산물 또는 이의 추출물도 비만 또는 비만 관련 질환을 예방, 개선 또는 치료하는데에 유용한 식의약 소재로 사용될 수 있다.
Abstract:
본 발명은 발효 더덕 추출물, 란세마사이드 A(lancemaside A), 에키노사이스틱산(echinocystic acid) 및 이들의 약학적 또는 식품학적으로 허용가능한 염으로 이루어진 군에서 선택되는 1종 이상을 유효 성분으로 포함하는 비만 또는 비만 관련 질환의 예방, 개선 또는 치료용 조성물을 제공한다. 본 발명에 따른 발효 더덕 추출물, 란세마사이드 A(lancemaside A), 에키노사이스틱산(echinocystic acid) 등은 약학 조성물 또는 기능성 식품 조성물을 구성하는 식의약적 소재로 사용될 수 있다. 특히, 본 발명에 따른 란세마사이드 A(lancemaside A), 에키노사이스틱산(echinocystic acid)은 AMPK(AMP-activated protein kinase)를 활성화시키고 지방합성 관련 유전자의 발현을 하향 조절시키기 때문에 전구지방세포의 지방세포로의 분화시 분화를 억제하는 효과 및 중성지질의 축적을 억제하는 효과가 우수하다.
Abstract:
The present invention relates to the novel use of Anemarrhena asphodeloides Bunge extract, and provided is a composition containing the Anemarrhena asphodeloides Bunge extract, a fraction thereof, or compounds isolated therefrom as active ingredients for the prevention or treatment of colitis. The Anemarrhena asphodeloides Bunge extract, the alcohol-soluble fraction thereof, or Mangiferin isolated from the Anemarrhena asphodeloides Bunge according to the present invention can be used as active ingredients for a pharmaceutical composition or a food composition, both of which are effective in the improvement of colitis symptoms or the prevention, delay and treatment of colitis, especially inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS).
Abstract:
The present invention relates to a novel use of galla rhois extract and the like, and provides a composition for preventing or treating colitis containing galla rhois extract as an active ingredient, a fraction thereof or a compound isolated therefrom. The galla rhois extract, a soluble fraction of galla rhois extract, glucose1,2,3,4,6-penta-O-galloyl-β-D-glucose isolated from galla rhois, or the like, can be used as an active ingredient of a pharmaceutical composition or a food composition, and in particular, can effectively prevent, delay, improve or treat inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) or the like.
Abstract:
The present invention provides a novel lactobacillus having anti-oxidative and anti-aging functions and a dementia-ameliorating effect, and more specifically, Lactobacillus pentosus var. plantarum C29 KCCM11291P and Lactobacillus curvatus C3 KCCM430009. Further, the present invention provides a pharmaceutical composition and a health functional food for anti-oxidation and anti-aging, wherein the pharmaceutical composition and the health functional food contain, as an active ingredient, Lactobacillus pentosus var. plantarum C29 KCCM11291P or Lactobacillus curvatus C3 KCCM430009, and provides a composition for preventing or treating dementia and a health functional food for preventing or ameliorating dementia, wherein the composition and the health functional food contain, as an active ingredient, Lactobacillus pentosus var. plantarum C29 KCCM11291P or Lactobacillus curvatus C3 KCCM430009. Further, the present invention provides a composition for preventing or treating dementia, wherein the composition contains, as an active ingredient, a fermented composition fermented by Lactobacillus pentosus var. plantarum C29 KCCM11291P or Lactobacillus curvatus C3 KCCM430009.
Abstract:
PURPOSE: A composition for preventing and treating neuropathic pain containing a ginseng originated saponin extract or saponin separated from the same is provided to apply the composition to produce health food. CONSTITUTION: Health food for preventing and treating neuropathic pain contains ginsenoside Rg3 denoted by chemical formula 3 as an active ingredient. In the chemical formula, R1 is Glc2-Glc and R2 is H. A composition for preventing and treating spinal cord injury contains 0.1-50wt% of ginseng originated saponin extract for the total amount of the composition. The composition for preventing and treating spinal cord injury can be produced into a form selected from: oral dosage forms including powder, granules, tablets, capsules, soft capsules, suspension, emulsion, syrup, or aerosol; and other dosage forms including external preparations, suppositories, or sterilized injection liquid.